Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (521-530 of 583) with videos related to

Pageof 59
Sort By:
Blood|October 24, 2002
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemiaGuido Marcucci, John C Byrd, Guowei Dai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|June 15, 2013
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemiaK H Metzeler, K Maharry, J Kohlschmidt, et al.
Leukemia|November 27, 2012
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemiaA Mims, A R Walker, X Huang, et al.
Leukemia|October 7, 2018
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRAChristopher J Walker, Christopher C Oakes, Luke K Genutis, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Leukemia|May 15, 2015
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemiaJ Khalife, H S Radomska, R Santhanam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, et al.
Leukemia|May 22, 2021
Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeqCaner Saygin, Eileen Hu, Pu Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemiaFriederike Pastore, Annika Dufour, Tobias Benthaus, et al.
Pageof 59

Showing results (521-530 of 583) with videos related to

Sort By:
Pageof 59
Blood|October 24, 2002
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemiaGuido Marcucci, John C Byrd, Guowei Dai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|June 15, 2013
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemiaK H Metzeler, K Maharry, J Kohlschmidt, et al.
Leukemia|November 27, 2012
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemiaA Mims, A R Walker, X Huang, et al.
Leukemia|October 7, 2018
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRAChristopher J Walker, Christopher C Oakes, Luke K Genutis, et al.
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Leukemia|May 15, 2015
Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemiaJ Khalife, H S Radomska, R Santhanam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, et al.
Leukemia|May 22, 2021
Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeqCaner Saygin, Eileen Hu, Pu Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemiaFriederike Pastore, Annika Dufour, Tobias Benthaus, et al.
Pageof 59